Literature DB >> 15845653

Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer.

Paul Thelen1, Jens-Gerd Scharf, Peter Burfeind, Bernhard Hemmerlein, Wolfgang Wuttke, Barbara Spengler, Volker Christoffel, Rolf-Hermann Ringert, Dana Seidlová-Wuttke.   

Abstract

Isoflavones have been shown to exert antiproliferative effects on cancer cells by steroid receptor signaling. In this study, we demonstrate the potential of plant constituents extracted from Belamcanda chinensis as anticancer drugs, which regulate the aberrant expression of genes relevant in proliferation, invasion, immortalization and apoptosis. LNCaP cells were treated with B.chinensis extract, tectorigenin or other isoflavones and mRNA expression was quantified by using real time RT-PCR. In addition, ELISA, TRAP assays and western blots were used to measure protein expression or activity. Male nude mice (n=18) were injected subcutaneously with LNCaP cells and were fed with extracts from B.chinensis, and tumor development was monitored versus a control animal group (n=18). Tectorigenin and several other phytochemicals downregulated PDEF, PSA and IGF-1 receptor mRNA expression in vitro. Furthermore, PSA secretion and IGF-1 receptor protein expression were diminished, and hTERT mRNA expression and telomerase activity decreased after tectorigenin treatments. However, TIMP-3 mRNA was upregulated on tectorigenin treatment. Growth of subcutaneous tumors in nude mice was delayed and diminished in animals fed with extracts from B.chinensis. The downregulation of PDEF, PSA, hTERT and IGF-1 receptor gene expression by tectorigenin demonstrates the antiproliferative potential of these agents. The upregulation of TIMP-3 gene expression indicates a pro-apoptotic function of the drug and a reduction of the invasiveness of tumors. The animal experiments demonstrate that B.chinensis markedly inhibited the development of tumors in vivo. Thus, these compounds may be useful for the prevention or treatment of human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845653     DOI: 10.1093/carcin/bgi092

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  13 in total

1.  [Antiandrogen strategies in prostate cancer: reconstitution of oestrogen receptor beta].

Authors:  P Thelen; A Strauss; M Stettner; S Kaulfuss; R-H Ringert; H Loertzer
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

2.  [Research in urologic university clinics. Assessment of current status and perspectives].

Authors:  K Miller; H Krause
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

3.  Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.

Authors:  Shuping Shuai; Shanlan Yue; Qingting Huang; Wei Wang; Junyi Yang; Ke Lan; Liming Ye
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-11       Impact factor: 2.441

4.  [Pharmacological potential of phytoestrogens in the treatment of prostate cancer].

Authors:  P Thelen; F Seseke; R-H Ringert; W Wuttke; D Seidlová-Wuttke
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

5.  The Antibacterial Assay of Tectorigenin with Detergents or ATPase Inhibitors against Methicillin-Resistant Staphylococcus aureus.

Authors:  Dae-Ki Joung; Su-Hyun Mun; Kuang-Shim Lee; Ok-Hwa Kang; Jang-Gi Choi; Sung-Bae Kim; Ryong Gong; Myong-Soo Chong; Youn-Chul Kim; Dong-Sung Lee; Dong-Won Shin; Dong-Yeul Kwon
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-28       Impact factor: 2.629

6.  Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.

Authors:  Adam W Nelson; Arnoud J Groen; Jodi L Miller; Anne Y Warren; Kelly A Holmes; Gerard A Tarulli; Wayne D Tilley; Benita S Katzenellenbogen; John R Hawse; Vincent J Gnanapragasam; Jason S Carroll
Journal:  Mol Cell Endocrinol       Date:  2016-11-23       Impact factor: 4.102

7.  Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer.

Authors:  Julia Gehrig; Silke Kaulfuß; Hubertus Jarry; Felix Bremmer; Mark Stettner; Peter Burfeind; Paul Thelen
Journal:  Oncotarget       Date:  2017-05-23

8.  Characterization and evaluation of a self-microemulsifying drug delivery system containing tectorigenin, an isoflavone with low aqueous solubility and poor permeability.

Authors:  Yunrong Zhang; Li He; Shanlan Yue; Qingting Huang; Yuhong Zhang; Junyi Yang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

9.  Phytoestrogens regulate the proliferation and expression of stem cell factors in cell lines of malignant testicular germ cell tumors.

Authors:  Astrid Hasibeder; Vivek Venkataramani; Paul Thelen; Heinz-Joachim Radzun; Stefan Schweyer
Journal:  Int J Oncol       Date:  2013-08-20       Impact factor: 5.650

10.  Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.

Authors:  Yu Guo; Ya-Hong Chen; Zhi-Hua Cheng; Huo-Niu Ou-Yang; Cong Luo; Zhi-Lin Guo
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.